--- a
+++ b/clusters/9knumclustersv2/clust_1331.txt
@@ -0,0 +1,111 @@
+Patients on supraphysiologic doses of steroids or use of such within the previous six weeks
+Are not using steroids for at least  days prior to trial treatment
+Patients who have any prior chemoimmunotherapy are not eligible; NOTE: the use of steroids to control the disease is permitted and does not have a washout period
+Previous treatment for ALL, except for prior steroids and/or hydroxyurea
+>=  weeks from protocol tissue procurement since resolution of all immune related toxicities and off systemic steroids >=  weeks; prophylactic use of steroids in preparation for radiologic exams are acceptable
+Patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary
+Subjects receiving prednisone or steroids must continue on the same dose they were receiving at the time of screening
+other lymphotoxic chemotherapy (including steroids except as below) within  weeks of enrollment
+Is on chronic systemic steroids.
+Patient may not have received prior systemic chemotherapy for LCH or other malignant disorder; systemic steroids equivalent to prednisone  mg/kg/day cannot have been given for more than  days in the  day period prior to study enrollment; however, patients who have only received surgical or radiation therapy, intralesional injection of steroids, or topical steroids may be enrolled
+For cohort  only (glioblastoma), patients must either not be receiving steroids, or be on a stable dose of steroids for at least five days prior to registration
+Patients may take steroids for disease control up to  hours prior to study enrollment; topical steroids are allowed for CTCL patients as described in inclusion criteria above
+There is no need for steroids and patients have not had steroids at least  weeks
+Has a diagnosis of immunodeficiency and is not on continuous daily immunosuppressive therapy within  days prior to the first dose of trial treatment; (subjects may receive steroids before or after SRS to prevent or manage cerebral edema; inhalational steroids are permitted)
+other lymphotoxic chemotherapy (including steroids except as below) within  weeks of enrollment
+Patients on systemic steroids (except if solely for adrenal replacement) within two weeks of collection
+There is no need for steroids and patients have not had steroids at least  weeks
+Subject using chronic systemic steroids greater than the equivalent of  mg of prednisone/prednisolone per day in the  weeks preceding study entry; replacement doses of steroids, topical, inhalational, nasal and ophthalmic steroids are permitted
+Steroids: patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary
+Any form of immunosuppressive therapy within  days prior to the first dose of trial treatment excluding steroids; attempts should be made to have patient on lowest possible dose of steroids; these medical entities can be exacerbated by PD- blockade
+Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents (e.g., interleukin , interferon alpha or gamma, granulocyte colony stimulating factors, etc.) within  days prior to study entry\r\n* NOTE: recent or current use of inhaled steroids is not exclusionary; if subjects are prescribed a brief course of oral corticosteroids, the use should be limited to less than  days; isolated use of steroids as premedication for medical procedures to minimize allergic reaction e.g. CT scan dye are allowed
+Patients may take steroids for disease control up to  hours prior to study enrollment
+Immunosuppressed state (e.g. HIV, use of chronic steroids)
+Patients may be on steroids prior to initiation of treatment, provided that, by cycle  day , steroids use was tapered down to less than or equal to  mg of prednisone
+If patients are taking systemic therapy for cGVHD at the time of enrollment, they must be receiving stable or tapering doses within the previous  weeks; patients are not required to have completed a course of steroids prior to enrollment
+If patient is on steroids, patient must be on a stable or decreasing dose of steroids for  days, no more than  mg dexamethasone (or equivalent) total per day at the time of screening and consent; if on steroids at the time of screening, the dose will need to be tapered and discontinued at least  days prior to CMV T cell infusion
+Concurrent use of systemic steroids or chronic use of immunosuppressant medications; recent or current use of inhaled steroids is not exclusionary
+Concurrent use of systemic steroids or immunosuppressant medications; recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary
+Concurrent use of systemic steroids or immunosuppressant medications; recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary
+Is in an immunosuppressed state (e.g. HIV +, use of chronic steroids [>  month])
+Patients must be at least  days post systemic steroids prior to enrollment
+Patient may be on steroids or anti-epileptics
+Concurrent use of systemic steroids or immunosuppressant medications
+Concurrent use of systemic steroids; recent or current use of inhaled steroids is not exclusionary
+Patients must be on stable dose of steroids for at least  days prior to baseline imaging
+Known immunosuppressed conditions or active immunosuppressive therapy such as organ transplantation (including bone marrow transplant), high dose steroids, or human immunodeficiency virus (HIV); although a documented negative HIV test is not mandatory for enrollment, patients felt to have a high clinical suspicion for HIV will need to test negative prior to enrollment; use of topicals or eye drops containing steroids is acceptable; inhaled steroids are excluded
+Patients must either not be receiving steroids, or be on a stable dose of steroids for at least five days prior to registration
+Chronic treatment with systemic steroids or another immunosuppressive agent with the following exceptions:\r\n* Intermittent steroids may be used on an as-needed basis (e.g. treatment for chemotherapy-related nausea)\r\n* Patients on physiologic replacement doses of steroids due to adrenal insufficiency for any reason may remain on these medications
+Concurrent use of systemic steroids with the exception of chronically administered steroids equivalent to ?  mg/day prednisone if patient has been on this therapy for ?month
+No steroids for at least  weeks prior to enrollment, and patient must not be expected to require steroids during the study period
+Patients on supraphysiologic doses of steroids or use of such =< weeks prior to registration
+Patients may not be receiving any steroids or other anti-immune therapy at the time of registration
+Patients requiring chronic systemic treatment with steroids
+Chronic treatment with steroids or any other immunosuppressant drugs
+Neurologic symptoms or imaging findings that necessitate the use of steroids on the day of enrollment or in the prior  days
+Concurrent radiation, with or without steroids, or steroids alone for emergency conditions secondary to lymphoma (i.e. cord compression, etc.) will be permitted
+Steroids for physiological replacement are allowed.
+Steroids: Therapeutic systemic doses of steroids must be stopped >  hours prior to CTL infusion. However, the following physiological replacement doses of steroids are allowed: <  mg/m/day hydrocortisone or equivalent
+Steroids: Therapeutic doses of steroids must be stopped >  hours prior to CTL infusion. However, the following physiological replacement doses of steroids are allowed: <  -  mg/m/day hydrocortisone or equivalent
+Is on chronic systemic steroids.
+Steroids: Therapeutic doses of steroids must be stopped >  hours prior to CTL infusion. However, the following physiological replacement doses of steroids are allowed: <  mg/m/day hydrocortisone or equivalent
+Concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within  days before the start of trial treatment. Short-term administration of systemic steroids (that is, for allergic reactions or the management of immune-related adverse events [irAE]) while on study is allowed. Also, subjects requiring hormone replacement with corticosteroids for adrenal insufficiency are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses <=  mg or equivalent prednisone per day. Note: Subjects receiving bisphosphonate or denosumab are eligible.
+Concurrent use of systemic steroids, through  hours post the last RNA CART infusion; recent or current use of inhaled steroids or physiologic replacement with hydrocortisone is not exclusionary\r\n* Therapeutic doses of steroids must be stopped >  hours prior to CTL infusion; however, the following physiological replacement doses of steroids are allowed: < - mg/m^/day hydrocortisone or equivalent
+Current treatment with steroids
+Long-term use of systemic corticosteroids; patients with replacement steroids and not immunosuppressive steroids may enroll in the study
+Current use of steroids
+Prior treatment with systemic steroids within  weeks prior to lymphodepletion (except for physiologic replacement doses for adrenal insufficiency, premedication for contrast allergies for scans, and for drug fever related to targeted therapy)
+Patients must have been off pharmacologic doses of systemic steroids for at least  days prior to enrollment; patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible; the only exception is for patients known to require  mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration in order to avoid allergic transfusion reactions; the use of conventional doses of inhaled steroids for the treatment of asthma is permitted, as is the use of physiologic doses of steroids for patients with known adrenal insufficiency
+Receipt of glucocorticoids (with the exception of inhaled glucocorticoid steroids for the use of allergic rhinitis or pulmonary disease) within  weeks of registration
+Has a known diagnosis of immunodeficiency (human immunodeficiency virus [HIV] / antibodies) or any other form of immunosuppressive therapy within  days prior to the first dose of trial treatment excluding steroids; attempts should be made to have patient on lowest possible dose of steroids
+History of contact dermatitis to clobetasol propionate or similarly fluorinated steroids or other steroids with the propionate ester
+Have used any systemic steroids within  days of study treatment
+Steroids: subjects with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary
+Chronic treatment with systemic steroids or another immunosuppressive agent; subjects with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary
+Patients who are on chronic steroids for unrelated conditions (i.e. rheumatologic conditions) are not eligible if their total daily dose of steroids is >=  mg prednisone
+Patients must not be on steroids other than for physiologic replacement
+Steroids for the treatment of hypersensitivity or transfusion reactions.
+Concurrent anticancer treatment or concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within  days before the start of trial treatment. Short-term administration of steroids (that is, for allergic reactions or the management of immune-related adverse events [irAE]) is allowed
+Patients must be on a stable or decreased dose of steroids for at least  days prior to baseline imaging
+Patients treatment with systemic steroids or another immunosuppressive agent; patients with endocrine deficiencies are allowed to receive physiologic or stress doses of steroids if necessary
+Concurrent use of systemic steroids; recent or current use of inhaled steroids is not exclusionary
+Used any systemic steroids within  days of study treatment
+Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents (e.g. interleukin-, interferon-alpha or gamma, granulocyte colony stimulating factors, etc.) within  days prior to study entry. NOTE: Recent or current use of inhaled steroids is not exclusionary. If subjects are prescribed a brief course of oral corticosteroids, the use should be limited to less than  days. Use of steroids before apheresis and immune assessment blood draws should be discouraged as it will affect white blood cell function.
+Subjects who require emergent use of systemic steroids, emergent surgery and/or radiotherapy
+Chronic treatment with systemic steroids or another immuno-suppressive agent
+Concurrent treatment with corticosteroids. If they are already on steroids, patients will be allowed to enroll on the study but will need to taper off as soon as possible.
+Is neurologically stable without the need for steroids for ? days before first dose of study treatment.
+Short term (< days) concurrent systemic steroids ?. mg/kg prednisone per day (maximum . mg/day) and bronchodilators (inhaled steroids) are permitted; other steroid regimens and/or immunosuppressives are excluded while receiving vaccine. Patients requiring steroids following previous CNS radiation for metastatic disease are excluded.
+Receipt of glucocorticoids (with the exception of inhaled glucocorticoid steroids for the use of allergic rhinitis or pulmonary disease) within  months prior to registration
+No concomitant therapy with steroids (replacement doses of steroids are allowed)
+Subject should not be receiving any agent for fatigue including steroids, megace or opioids. NOTE: Subjects who have a contrast-induced allergy are allowed to receive steroids for their scans.
+Subject does not require steroids or does not require escalating doses of steroids for at least  weeks prior to the first dose of study drug.
+Patients who have received systemic steroids within  weeks prior to starting study treatment
+Chronic treatment with steroids or other immunosuppressive agents for medical conditions other than cancer. Patients who require steroids for treatment of tumor-associated cerebral edema are eligible.
+Received systemic steroids within  days of study enrollment
+If a patient had been taking steroids, at least  weeks must have passed since the last dose; patients stable on physiologic replacement doses of steroids or other forms of hormone replacement therapy are eligible
+Patients can be on steroids as long as the dose has been stable for >=  days
+Concurrent use of systemic steroids
+Current treatment with steroids
+Patients must have not received any prior therapy other than surgery and/or steroids
+Used any systemic steroids within  days of study treatment
+Patients may be on steroids prior to initiation of treatment as long as by cycle  day  steroids use was tapered down less than or equal to  mg of prednisone
+Concurrent steroids are allowed if dexamethasone dose is =< mg daily; if feasible, steroids should be weaned off once sorafenib has been initiated
+Systemic steroids within  week before enrollment except steroids used as part of an antiemetic regimen or maintenance-dose steroids for non-cancerous disease.
+Patients on concurrent steroids, other than those allowed for routine antiemetics, or inhaled steroids
+Current treatment with steroids
+Patients receiving chronic treatment with oral steroids or another immunosuppressive agent (excluding steroids as part of the chemotherapy pre-medication or emetic medication)
+Use of systemic steroids, or other pharmacological agents such as methylphenidate for cancer-related fatigue
+Patients who have not completed their initial steroids
+Patients may be on steroids at study entry
+Patients continuously taking systemic steroids within the last  days
+No concurrent use of chronic systemic steroids (defined as currently on more than  week of treatment)
+Patients must be scheduled for tapering doses of (or no longer treated with):\r\n* Cyclosporine;\r\n* Tacrolimus;\r\n* Sirolimus;\r\n* Steroids (patients may be on physiologic doses of steroids)
+Use of oral or systemic steroids or other anti?immune therapy =<  days prior to pre?registration; Note: Use of inhaled/nasal steroids is not exclusionary
+Patients must be at least  days post systemic steroids prior to enrollment
+Patients must not have been taking steroids or are on a stable dose of steroids for at least  days before enrollment
+Systemic steroids at physiologic doses (equivalent to dose of oral prednisone  mg) are permitted. Steroids as anti-emetics for chemotherapy are not allowed.
+Patients with known immunodeficiency, known autoimmune disease, or concurrent use of immunomodulatory agents including systemic steroids within  days prior to registration, are ineligible
+Taking ibuprofen, naproxen, other non-steroid anti-inflammatory drugs (NSAIDs), steroids (except inhaled steroids) within  days of study registration
+Current treatment with steroids (must be discontinued  week before starting IFN gamma)
+Systemic treatment with steroids or other immunosuppressive agents within  days prior to entry. Physiological replacement with hydrocortisone or equivalent is acceptable.